Related Experiment Videos
Pharmacological management of erectile dysfunction.
F Montorsi1, A Salonia, F Deho'
1Departments of Urology, University Vita-Salute San Raffaele, Milan, Italy. montorsi.francesco@hsr.it
BJU International
|February 27, 2003
Summary
Erectile dysfunction (ED) treatments include oral medications like sildenafil, apomorphine SL for mild to moderate cases, and newer phosphodiesterase type 5 inhibitors. Alternative therapies include intracavernosal and intraurethral alprostadil for non-responders.
Area of Science:
- Urology
- Pharmacology
Background:
- Erectile dysfunction (ED) is a prevalent condition impacting millions globally.
- Oral pharmacotherapy is the primary treatment for most ED patients.
- Sildenafil, a phosphodiesterase type 5 inhibitor, is a widely used and effective oral agent for ED.
Purpose of the Study:
- To review current and emerging pharmacotherapies for erectile dysfunction.
- To discuss the efficacy and safety profiles of various ED treatment options.
- To highlight alternative treatments for patients unresponsive to oral medications.
Main Methods:
- Review of existing literature on erectile dysfunction treatments.
- Analysis of pharmacological agents including phosphodiesterase type 5 inhibitors and dopamine agonists.
- Evaluation of intracavernosal and intraurethral therapies.
Main Results:
- Sildenafil demonstrates a favorable efficacy-safety profile for ED.
- Apomorphine SL is suitable for mild to moderate ED.
- Vardenafil and tadalafil show promising efficacy and safety.
- Alprostadil is a key drug for injection and intraurethral ED therapies.
- Second-line treatments show high efficacy, but patient attrition is notable.
Conclusions:
- A range of effective pharmacotherapies exist for erectile dysfunction.
- Oral agents like sildenafil are first-line treatments.
- Alternative therapies are available for patients who do not respond to or cannot use oral medications.
- Continued research and development are yielding new treatment options for ED.